Literature DB >> 18277387

Renal cytochrome P450 as a determinant of impaired natriuresis by PPAR-gamma ligands in ovariectomized obese rats.

Kyoko Yoshioka1, Shu Wakino, Koichiro Homma, Takeshi Kanda, Satoru Tatematsu, Kazuhiro Hasegawa, Naoki Sugano, Osamu Ito, Ken Omata, Takao Saruta, Koichi Hayashi.   

Abstract

OBJECTIVE: Peroxisome proliferator-activated receptor (PPAR)-gamma ligand, pioglitazone (PIO), is reported to induce edema especially in postmenopausal women. The aim of this study was to elucidate the mechanism for PIO-induced sodium retention and to discover the therapeutic strategy for the PIO-induced changes in renal sodium handling. METHODS AND PROCEDURES: Zucker obese rats were ovariectomized and were given PIO for 8 weeks. Renal sodium excretion and renal expressions of several enzymes that generate natriuretic substances were examined.
RESULTS: Sodium excretion was decreased in ovariectomized (OVX) rats that were given PIO when compared with OVX rats that were not. Urinary nitrites/nitrates excretion was decreased in OVX rats, but was restored by PIO. The expressions of nitric oxide synthases (NOSs) and cyclooxygenases-1/2 (COX-1/2) were unaltered. Similarly, the expression of epithelial sodium channels (ENaC), identified as a PPAR-gamma-regulated gene product, was unaffected. In contrast, the expression of cytochrome P450 4A (CYP4A) was increased in OVX rats, and was downregulated by PIO. Co-treatment of OVX rats with PIO and PPAR-alpha ligand, fenofibrate, a putative inducer of CYP4A, restored not only the impaired sodium excretion but also the downregulated CYP4A expression. DISCUSSION: PIO-induced sodium retention is specific in female OVX rats. Ovariectomy decreases renal NO production, but upregulates renal CYP4A expression to compensate for renal sodium balance. In this setting, PIO downregulates CYP4A, leading to sodium retention. Furthermore, PPAR-alpha ligands can provide a novel strategy for preventing the PIO-induced sodium retention.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18277387     DOI: 10.1038/oby.2008.18

Source DB:  PubMed          Journal:  Obesity (Silver Spring)        ISSN: 1930-7381            Impact factor:   5.002


  5 in total

1.  Regulation of ENaC-Mediated Sodium Reabsorption by Peroxisome Proliferator-Activated Receptors.

Authors:  Tengis S Pavlov; John D Imig; Alexander Staruschenko
Journal:  PPAR Res       Date:  2010-06-14       Impact factor: 4.964

Review 2.  PPARgamma and its ligands: therapeutic implications in cardiovascular disease.

Authors:  Luis Villacorta; Francisco J Schopfer; Jifeng Zhang; Bruce A Freeman; Y Eugene Chen
Journal:  Clin Sci (Lond)       Date:  2009-02       Impact factor: 6.124

Review 3.  Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug.

Authors:  Lorenzo Nesti; Domenico Tricò; Alessandro Mengozzi; Andrea Natali
Journal:  Cardiovasc Diabetol       Date:  2021-05-18       Impact factor: 9.951

4.  Rosiglitazone treatment restores renal responsiveness to atrial natriuretic peptide in rats with congestive heart failure.

Authors:  Ilia Goltsman; Emad E Khoury; Doron Aronson; Omri Nativ; Giora Z Feuerstein; Joseph Winaver; Zaid Abassi
Journal:  J Cell Mol Med       Date:  2019-05-13       Impact factor: 5.310

5.  Thiazolidinedione-induced fluid retention: recent insights into the molecular mechanisms.

Authors:  Jerzy Bełtowski; Jolanta Rachańczyk; Mirosław Włodarczyk
Journal:  PPAR Res       Date:  2013-03-18       Impact factor: 4.964

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.